Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

65992 1510824253HCLSReviewUkraineNovember2017.pdf
Energy Boardroom

GSK ditches ovarian cancer plans for Votrient

01.04.2014 / Fierce Pharma

GlaxoSmithKline said Monday that after reviewing data from a Phase III trial, it has withdrawn its application to the European Medicines Agency seeking to expand approval of Votrient to include women with advanced ovarian cancer.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: